Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D W FRY

Showing results (61-70 of 90) with videos related to

Pageof 9
Sort By:
Advances in Enzyme Regulation|January 1, 1989
Biochemical pharmacology and antitumor properties of 4-amino-8-[beta-D-ribofuranosylamino]pyrimido-[5,4-d]pyrimidineR C Jackson, T J Boritzki, P D Cook, et al.
Advances in Enzyme Regulation|January 1, 1985
The biochemical pharmacology of CI-920, a structurally novel antibiotic with antileukemic activityR C Jackson, D W Fry, T J Boritzki, et al.
Investigational New Drugs|January 1, 1985
Dezaguanine mesylate: a new antipurine antimetaboliteW R Leopold, D W Fry, T J Boritzki, et al.
Journal of Medicinal Chemistry|June 24, 1994
Tyrosine kinase inhibitors. 3. Structure-activity relationships for inhibition of protein tyrosine kinases by nuclear-substituted derivatives of 2,2'-dithiobis(1-methyl-N-phenyl-1H-indole-3-carboxamide)G W Rewcastle, B D Palmer, E M Dobrusin, et al.
Journal of Medicinal Chemistry|May 9, 1997
Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of bindingB D Palmer, S Trumpp-Kallmeyer, D W Fry, et al.
Journal of Medicinal Chemistry|September 1, 1995
Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptorG W Rewcastle, W A Denny, A J Bridges, et al.
The Journal of Biological Chemistry|June 11, 1998
Role of tyrosine kinase activity of epidermal growth factor receptor in the lysophosphatidic acid-stimulated mitogen-activated protein kinase pathwayJ M Cunnick, J F Dorsey, T Standley, et al.
Journal of Medicinal Chemistry|August 20, 1993
Tyrosine kinase inhibitors. 1. Structure-activity relationships for inhibition of epidermal growth factor receptor tyrosine kinase activity by 2,3-dihydro-2-thioxo-1H-indole-3-alkanoic acids and 2,2'-dithiobis(1H-indole-3-alkanoic acids)A M Thompson, G W Rewcastle, M Tercel, et al.
Anti-Cancer Drug Design|August 1, 1994
Strategies for the discovery of novel tyrosine kinase inhibitors with anticancer activityD W Fry, A J Kraker, R C Connors, et al.
Advances in Enzyme Regulation|January 1, 1984
Biochemical pharmacology of the lipophilic antifolate, trimetrexateR C Jackson, D W Fry, T J Boritzki, et al.
Pageof 9

Showing results (61-70 of 90) with videos related to

Sort By:
Pageof 9
Advances in Enzyme Regulation|January 1, 1989
Biochemical pharmacology and antitumor properties of 4-amino-8-[beta-D-ribofuranosylamino]pyrimido-[5,4-d]pyrimidineR C Jackson, T J Boritzki, P D Cook, et al.
Advances in Enzyme Regulation|January 1, 1985
The biochemical pharmacology of CI-920, a structurally novel antibiotic with antileukemic activityR C Jackson, D W Fry, T J Boritzki, et al.
Investigational New Drugs|January 1, 1985
Dezaguanine mesylate: a new antipurine antimetaboliteW R Leopold, D W Fry, T J Boritzki, et al.
Journal of Medicinal Chemistry|June 24, 1994
Tyrosine kinase inhibitors. 3. Structure-activity relationships for inhibition of protein tyrosine kinases by nuclear-substituted derivatives of 2,2'-dithiobis(1-methyl-N-phenyl-1H-indole-3-carboxamide)G W Rewcastle, B D Palmer, E M Dobrusin, et al.
Journal of Medicinal Chemistry|May 9, 1997
Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of bindingB D Palmer, S Trumpp-Kallmeyer, D W Fry, et al.
Journal of Medicinal Chemistry|September 1, 1995
Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptorG W Rewcastle, W A Denny, A J Bridges, et al.
The Journal of Biological Chemistry|June 11, 1998
Role of tyrosine kinase activity of epidermal growth factor receptor in the lysophosphatidic acid-stimulated mitogen-activated protein kinase pathwayJ M Cunnick, J F Dorsey, T Standley, et al.
Journal of Medicinal Chemistry|August 20, 1993
Tyrosine kinase inhibitors. 1. Structure-activity relationships for inhibition of epidermal growth factor receptor tyrosine kinase activity by 2,3-dihydro-2-thioxo-1H-indole-3-alkanoic acids and 2,2'-dithiobis(1H-indole-3-alkanoic acids)A M Thompson, G W Rewcastle, M Tercel, et al.
Anti-Cancer Drug Design|August 1, 1994
Strategies for the discovery of novel tyrosine kinase inhibitors with anticancer activityD W Fry, A J Kraker, R C Connors, et al.
Advances in Enzyme Regulation|January 1, 1984
Biochemical pharmacology of the lipophilic antifolate, trimetrexateR C Jackson, D W Fry, T J Boritzki, et al.
Pageof 9